progress in virology · 0910–0915 introduction chairs: professor anna maria geretti, institute of...

Executive Chair: Honorary Chair:

Professor Anna Maria Geretti Professor Jonathan WeberInstitute of Infection and Global Health Imperial College London

University of Liverpool

Wednesday 16 September 2015

Wellcome Collection · London

19th Annual Resistance andAntiviral Therapy Meeting19th Annual Resistance andAntiviral Therapy Meeting

ResistanceAntiviral TherapyResistance

Antiviral TherapyandandandResistance

Antiviral Therapy

6 CPD

Credits

Unique R

eference No:

98848

PROGRESS IN VIROLOGYPROGRESS IN VIROLOGY

FINAL PROGRAMME

Introduct ion

2



Antiviral Therapy

Conference Organiser: t: 020 8446 8898 | f: 020 8446 9194FINAL PROGRAMME 2015 e: [email protected] | www.mediscript.ltd.uk

Contents

Programme 3,4

Conference 5,6Information

Biographies 7–9

Sponsors 12

LocationsLower Ground Floor

Lecture Theatre:Henry Wellcome

Auditorium

Exhibition:Williams Lounge

Lunch andRefreshments:

Williams Lounge

Dear Colleague

Welcome to the 19th Annual Resistance and Antiviral Therapy

Meeting at the Wellcome Collection. Located on Euston Road,

London, the conference centre provides all the facilities required for our

delegates.

We would like to thank our colleagues on the Scientific Committee

for preparing an excellent programme, covering a very wide range of

topics. This year’s programme focuses on recent advances in HIV

treatment and pathogenesis and also addresses hepatitis C co-infection.

A session dedicated solely to UK-led research also offers a selection of our

speakers to present their yet-to-be published work in progress. We feel

that the programme will prove topical as well as raise many interesting

points for debate and discussion.

We are especially delighted that so many eminent speakers

have agreed to come to London to share their latest research.

Our international speakers include Professor Andrea De Luca,

Dr Miriam Lichtner, Dr José Luis Blanco Arévalo and Dr Marije Hofstra.

We would like to thank all of our speakers for their invaluable

contribution in helping to make the conference what we hope will be a

great success.

Finally, we would like to thank all of our sponsors and exhibitors for

their continued support of the conference, which, in part, enables us to

facilitate the attendance of a number of international speakers.

We hope that you enjoy the conference and find it of relevance to both

your educational and your practical needs.

Professor Anna Maria Geretti Professor Jonathan WeberExecutive Chair Honorary Chair

Dr Marta Boffito Chelsea and Westminster Hospital, London

Professor David Dunn MRC Clinical Trials Unit, London

Professor Geoff Dusheiko Royal Free Hospital, London

Professor Anna Maria Geretti Institute of Infection and Global HealthExecutive Chair University of Liverpool

Professor William Irving University of Nottingham

Professor Saye Khoo University of Liverpool

Professor Jonathan Weber Honorary Chair Imperial College London

Scientific Committee

Res

ista

nce MEDICAL EDUCATION

PublishingConferencesSecretariat www.mediscript.ltd.uk

6 CPD CreditsUnique

reference number:

98848

mailto:[email protected]

http://www.mediscript.ltd.uk


Programme

Wednesday 16 September 2015

Wellcome Collection · 183 Euston Road · London NW1 2BE

0830 Registration and exhibition open

0910–0915 IntroductionChairs: Professor Anna Maria Geretti, Institute of Infection and Global Health,


Chairs: Professor Jonathan Weber, Imperial College London

0915–0940 A year in review. HIV and HIV co-infection with HCV: scientific advancesthat will change clinical practiceProfessor Andrea de Luca, University of Siena, Italy

0940–0950 Analysis and discussion

Session 1: Virological aspects of HIV pathogenesis

0950–1015 Is cytomegalovirus a significant co-factor in HIV infection and disease?Dr Miriam Lichtner, Sapienza University of Rome, Italy

1015–1040 How is the HIV reservoir maintained during long-term ART?Dr John Frater, University of Oxford


1055–1115 Morning coffee

Session 2: Virological aspects of HIV therapy

1115–1140 Host cell antivirals: ideas for the next pipeline?Professor Áine McKnight, Barts and The London School of Medicine and Dentistry

1140–1205 Is drug resistance a threat to PrEP programmes?Dr Marta Boffito, Chelsea and Westminster Hospital, London

1205–1230 What is new on resistance to the integrase inhibitors?Dr José Luis Blanco Arévalo, Hospital Clinic, University of Barcelona


1245–1340 Lunch & exhibition

Keynote Lecture

Chair: Professor Anna Maria Geretti, Institute of Infection and Global Health,University of Liverpool

1340–1410 The influence of HIV on HCV: from virus replication to treatment outcomes

Professor Geoff Dusheiko, Royal Free Hospital, London

3



Antiviral Therapy




Programme

Session 3: UK research in progress: HIV and co-infections

Chairs: Dr John Frater, University of Oxford

Chairs: Dr Alessandro Cozzi-Lepri, University College, London

1410–1530 10-minute presentations of emerging data

• Evolution of HIV-1 under interferon-alpha treatmentDr Tomas Doyle, King’s College London

• Global epidemiology of drug resistance following failure of tenofovir-containingWHO recommended regimens for adult HIV-1 infectionDr Ravi Gupta, University College London

• Does subtype C virus increase the risk of virological failure on first-line TDF-containing regimens?Professor David Dunn, MRC Clinical Trials Unit, London

• Long-term virological outcomes among ART-experienced patients receivingraltegravir in a large European cohort studyMs Anna Schultze, University College London

• Treatment-emergent resistance during prolonged failure of NNRTI-based ARTDr Alex Stockdale, University of Liverpool

• The impact of HLA Class I on virological outcomes of HBV infectionDr Philippa Matthews, University of Oxford

• Resistance variants in HCV-infected patients receiving all-oral therapyDr Ana Filipe, University of Glasgow

• Exploring the interaction of HIV with human endogenous retrovirusesDr Gkikas Magiorkinis, University of Oxford


1545–1605 Afternoon tea

Session 4: Debates in HIV care

Chairs: Professor Saye Khoo, University of Liverpool

Chairs: Dr Yvonne Gilleece, Brighton and Sussex University Hospitals NHS Trust

1605–1620 Which single-tablet regimen for which patient?

Presenter:Dr Tristan Barber, Chelsea and Westminster Hospital, London

Discussant:Dr Marta Boffito, Chelsea and Westminster Hospital, London

1620–1640 Which level of plasma viral load for defining virological failure?

Presenter:Dr Marije Hofstra, Luxembourg Institute of Health, and University Medical Center Utrecht

Discussant:Professor Andrea de Luca, University of Siena, Italy

1640–1655 Debate and audience vote

1655–1700 CloseProfessor Anna Maria Geretti, Institute of Infection and Global Health,


Professor Jonathan Weber, Imperial College London

4



Antiviral Therapy




Conference Information

Registration

The registration fee includes access to all scientific sessions, the exhibition area, lunch and refreshments throughout

the conference.

Delegate badges

Badges must be worn at all times to gain access to the lecture theatre, catering and exhibition areas.

Continuing Professional Development (CPD)

Medical staff in career-grade posts who are enrolled with one of the Federations of Royal Colleges for Continuing

Professional Development can receive CPD credits at the rate of one CPD credit per hour (exclusive of travel,

refreshments or social activities). The conference has been allocated 6 CPD credits with the unique reference code:

98848. Certificates for attendance will be supplied in the conference pack that will be handed to you at the

registration desk.

Scholarships

Community Registration Places have been allocated to delegates attending the conference, on the basis of a

maximum of one free-of-charge registration per community group.

Student Registration Scholarships The conference has supported the registrations of three delegates, who are

students, to attend the 19th Annual Resistance and Antiviral Therapy Meeting. These awards were made available

to delegates who, through their applications, clearly showed they had financial constraints that would otherwise

have prevented them from attending the conference.

WiFi connectivity

Free WiFi access will be available at the conference venue.

Cloakroom

A manned cloakroom is available onsite, which is located on the ground floor of the Wellcome Collection. Personal

items can be deposited free of charge. All belongings are left at the owner’s risk. The conference organisers do not

accept responsibility for the loss of, or damage to, delegates’ personal property stored in the cloakroom area.

Exhibition

The exhibition represents an integral element of the conference, providing participants with an excellent platform for

networking as well as an opportunity to gain further insight into cutting-edge technology, the latest healthcare

solutions, and services within the fields of HIV, viral hepatitis and GU medicine. Entrance to the exhibition hall is

free for all registered delegates.

Filming and photography

Please note that some still photography may take place at the conference. This might include general coverage of

registration, the exhibition and the lecture theatre. This material may be published either in Mediscript Ltd

publications or on the Mediscript Ltd website.

5



Antiviral Therapy




Conference Information

Wellcome Collection · 183 Euston Road · London NW1 2BE

telephone: +44 (0)20 7611 2222 · web: wellcomecollection.org

Travel

The conference venue is in a convenient andattractive location in the centre of London, easilyaccessible by all forms of transport.

The Collection is a short walk from Euston,King’s Cross and St Pancras Internationalmainline stations and is additionally served byunderground stations at Euston Square andWarren Street.

Car parking is available nearby: details areavailable from the NCP. There are also good linksto the city centre from both Heathrow andGatwick airports. Journeys from either Heathrowor Gatwick take approximately an hour.

The Collection’s main entrance and reception face Euston Road.

By London Underground:

Euston Square: Station on the Circle, Metropolitan and Hammersmith & City lines (2 minutes’ walk)

Euston: Station on the Victoria and Northern lines (2 minutes’ walk)

Warren Street: Station on the Victoria and Northern lines (5 minutes’ walk)

King’s Cross/St Pancras: Station on the Circle, Piccadilly, Hammersmith & City, Northern, Metropolitan andVictoria lines (10 minutes’ walk)

By National Rail:

Euston: Station (2 minutes’ walk)

King’s Cross: Station (10 minutes’ walk)

St Pancras International: Station (10 minutes’ walk)

By air:

Heathrow: Express train from Heathrow airport (15 minutes to Paddington station, then four stopson the Underground [Circle Line] to Euston Square station)

Gatwick: Express train from Gatwick airport (30 minutes to Victoria station, then three stops onthe Underground [Victoria Line] to Warren Street station)

Stansted: Express train from Stansted airport (45 minutes to Liverpool Street, then five stops onthe Underground [Circle Line] to Euston Square station)

6



Antiviral Therapy


http://wellcomecollection.org



Biographies

Tristan Barber is currently working as an HIV/GUM Consultant at Chelsea and Westminster NHSFoundation Trust. He has a research background in HIV-related neurocognitive impairment andPhase 3 clinical trials at Imperial College London and the St Stephen's AIDS Trust.

José Luis Blanco Arévalo is a Specialist in Internal Medicine at Hospital Clinic, University of Barcelonaand received his PhD from the University of Barcelona. His research areas include HIV resistance andsalvage therapy, sexually transmitted diseases, and anal cancer prevention. He is currently a Professorin the Department of Medicine and the Masters programme of AIDS at the University of Barcelona.He also serves as a Senior Specialist in the Department of Infectious Diseases at the Hospital Clinic inBarcelona. He is the coordinator of the Spanish Network of HIV Resistance Research (RIS) and thecounsellor at the HIV Programme of the Fundación Vicente Ferrer (NGO) in Anantapur,Andhra Pradesh, India. He was a Fellow in Infectious Diseases at Stanford University, California,USA. He is also the author of numerous articles in peer-reviewed medical journals.

Marta Boffito graduated from the University of Turin, Italy in Medicine and trained in general medicineand infectious diseases at the University of Turin and at the University of California at San Francisco,California, USA (with the Department of HIV at the General Hospital). She became a specialist inInfectious Diseases/HIV in 2001. Marta obtained her PhD in 2004 at the University of Liverpool, UK(Department of Pharmacology and Therapeutics) with a thesis entitled ‘Clinical Pharmacology ofHuman Immunodeficiency Virus-1 Protease Inhibitors’, which covered the pharmacokinetics andpharmacodynamics of antiretroviral therapy. Currently, she is the Clinical Lead of the HIV ResearchUnit at St Stephen’s Centre, a Consultant Physician at Chelsea and Westminster Hospital, and a Readerat Imperial College London, where, in addition to her clinical duties, she is heavily involved innumerous clinical studies.

Andrea De Luca graduated in Medicine in 1989, specialising in infectious diseases. He is Professor ofInfectious Diseases at the University of Siena, Italy. Since 2011 Andrea has been the Director of theUniversity Infectious Diseases Clinic at Siena University Hospital. He has published more than260 scientific papers, made over 400 conference presentations and is the author of several chapters intextbooks of infectious diseases. Andrea has been Principal Investigator in several clinical studies andtrials. His research topics are the clinical aspects of HIV infection, antiretroviral therapy, antiviraldrug resistance and pharmacokinetics, treatment of HCV, opportunistic and CNS infections.

Tomas Doyle is a Registrar in Clinical Virology. He is currently working towards a PhD withMichael Malim on the interferon-α-induced block to HIV replication, on a Wellcome Trust Fellowship.Tomas’ research interests include the pathogenesis and treatment of HIV-1 and other persistent viralinfections.

Geoff Dusheiko is Emeritus Professor of Medicine at the Royal Free Hospital and University CollegeSchool of Medicine, London, UK. He earned his Bachelor of Medicine, Bachelor of Surgery degreefrom the University of Witwatersrand in Johannesburg, South Africa. After graduating, he completedhis internship at Baragwanath Hospital in Johannesburg and his residency at Johannesburg Hospital.His fellowships were conducted at the Johannesburg Hospital Liver Unit and the National Institutesof Health in Maryland and the University of Minnesota, USA. Professor Dusheiko's research interestsinclude the management and treatment of hepatitis B and C and small hepatocellular carcinoma; hehas a special interest in research in viral hepatitis, focused on viral genotyping, applied molecularvirology, the natural history of chronic viral hepatitis, and antiviral therapies. He has served oneditorial boards for the Journal of Viral Hepatitis, Hepatology, and Best Practice and Research:Clinical Gastroenterology, Gut among others, and is the author of more than 330 published articles.He is currently a co-editor of Alimentary Pharmacology and Therapeutics and on the editorial board

7



Antiviral Therapy




Biographies

of the Journal of Viral Eradication. A member of several organisations, including IASL, AASLD, andEASL, he is a fellow of the Royal College of Physicians, the Royal College of Physicians of SouthAfrica, and the Royal College of Physicians of Edinburgh. He has served as Educational Councilloron the Governing Board of the European Association for the Study of the Liver for the past 4 yearsand was the recipient of the EASL recognition award in 2014. He is a director of the Skipton Fundand is a guidelines writer for the WHO.

David Dunn is Professor of Medical Statistics at the MRC Clinical Trials Unit at UCL. He is the co-PrincipalInvestigator of the UK HIV Drug Resistance Database. David’s other research interests include HIVprevention, hepatitis B infection, and the methodology of randomised controlled trials.

Ana Filipe has been working in the field of hepatitis C over the last 7 years. Her earlier studies focused onin vitro models as tools to understand the various stages of the hepatitis C virus life cycle. Ana’s mostrecent research focuses on HCV genetics with the aim of understanding how genomic variability mayaffect response to treatment. Following on from her earlier studies she has a keen interest in livermetabolism during infection.

John Frater is an MRC Senior Clinical Fellow and Associate Professor, based at the Peter Medawar Buildingat the University of Oxford. He is the scientific lead and co-chair of ‘CHERUB’, an NIHR-supportedcollaboration dedicated to finding a cure for HIV infection. John also works as an HonoraryConsultant Physician at the Oxford University Hospitals Trust.

Anna Maria Geretti is Professor of Virology and Infectious Diseases at the Institute of Infection and GlobalHealth of the University of Liverpool, and Honorary Consultant at the Royal Liverpool UniversityHospital, where she consults on virus infections, sees patients with HIV or chronic viral hepatitis,teaches and conducts research. Anna Maria trained in Italy, the Netherlands, and the UK and has aspecial interest in HIV, hepatitis B and hepatitis C infection. In these areas she contributes to theeducational, scientific, and guideline-formulation activities of national and international specialistsocieties and advisory bodies including the British HIV Association (BHIVA), the British Associationfor Sexual Health and HIV (BASHH), and the European AIDS Clinical Society (EACS). She waselected to the EACS Governing Board in 2009, and in 2012 was elected EACS Secretary. She is alsoa founding member of the recently formed British Society for Nanomedicine. Her research interestsfocus on antiviral therapy and drug resistance, virus genetic variability, viral co-infections andmolecular diagnostics. Anna Maria has published over 200 peer-reviewed articles, editorials, reviewsand book chapters, runs capacity building programmes for resource-limited countries, andenthusiastically shares her expertise to train doctors and scientists.

Ravi Gupta is an infectious diseases clinician and molecular virologist with a focus on HIV. He was recentlyawarded a Wellcome Senior Fellowship in Clinical Science to commence in 2016. Ravi’s work on HIVdrug resistance has been aimed at resource-limited regions, and with particular focus on proteaseinhibitors, and more recently tenofovir resistance following first-line ART failure.

Marije Hofstra specialises in Medical Microbiology at the University Medical Center Utrecht, in theNetherlands. She is a researcher in the Translational Virology Group in Utrecht as well as in theDepartment of Infection and Immunity of the Luxembourg Institute of Health, where she works onlow-level viraemia and transmission of HIV. Marije is currently the daily coordinator of the SPREADprogramme, a European surveillance programme for transmitted HIV drug resistance.

8



Antiviral Therapy




Biographies

Miriam Lichtner graduated in medicine in 1994 and specialised in infectious diseases. She obtained a PhDin 2003 and spent 2 years at the Cochin Institute in Paris. Since 2009 she has been Assistant Professorof Infectious Diseases, at the Sapienza University of Rome, Italy. Miriam works in the InfectiousDisease Unit of Latina, Italy for the clinical part of her work. Miriam has published more than160 scientific papers and her research activity has focused mainly on natural immunity of HIVinfection, tuberculosis, hepatitis and CMV.

Gkikas Magiorkinis is a Clinical Research Fellow in the University of Oxford and Honorary Consultantat PHE. He has been supported through the MRC’s Clinician Scientist Fellowship to study thepathophysiological roles of human endogenous retroviruses. Gkikas received the first MarieSklodowska-Curie Prize in 2012 from the European Commission.

Philippa Matthews is a newly appointed Consultant in Infectious Diseases and Microbiology in Oxford.Alongside her clinical work, she is developing her research interest in the natural history, epidemiologyand immunology of chronic viral infections in southern African populations, with a particular focuson HBV and HIV.

Áine McKnight is Professor of Viral Pathology at Barts & The London School of Medicine, QMUL. Hercurrent research focus is on the characterisation of intrinsically expressed cellular factors that preventthe replication of HIV in human cells. She also characterises how HIV mitigates such cellular factors.This research is important not only to our understanding of the biology of HIV infection, but also togive us insights into the weaknesses in the viral replication cycle and possible targets for antiviraltherapy.

Anna Schultze is currently completing a PhD at UCL, looking at the epidemiology and clinicalconsequences of HIV drug resistance using data from large HIV cohort studies, primarily theEuroSIDA study.

Jonathan Weber is Vice Dean (Research) for the Faculty of Medicine at Imperial College London, Directorof the Imperial Academic Health Science Centre, Director of the Imperial Biomedical Research Centre,and Director of Research for the Imperial College Healthcare NHS Trust. Professor Weber isresponsible for the pipeline of biomedical translation at Imperial, with a focus on stratification andpatient characterisation. His own research area is in infectious diseases with a particular focus on theprevention of HIV infection. Jonathan co-led the UK MRC /DFID Microbicide DevelopmentProgramme and was the Principal Investigator for the Wellcome Trust SPARTAC project, whichdefined the role of antiretroviral therapy at primary HIV infection. He is now leading the UK HIVVaccine Consortium, developing prime-boost HIV vaccine candidates.

9



Antiviral Therapy




Notes

10



Antiviral Therapy




Notes

11



Antiviral Therapy




19th Annual Resistance & Antiviral Therapy Meetingis organised and administered by

Mediscript Ltd

MEDICAL EDUCATIONPublishing · Conferences · Secretariat

Gold SponsorThe Scientific Committee would like to extend grateful thanks

to the Gold Sponsor of this meeting for providing aneducational grant in support of the programme

Gilead Sciences Ltd

280 High HolbornLondon WC1V 7EE

Supported by Gilead, who provided fundingGilead has had no input into the content of the materials used at this meeting

Pub

licat

ion

date

:S

epte

mbe

r20

15·

v10

Fina

lPro

gram

me

·20

15P

RO

GR

ES

SIN

VIR

OLO

GY

The Scientific Committee also wish to express their thanks to the following companiesfor their generous support:

Bronze Sponsors

Janssen50–100 Holmers Farm WayHigh WycombeBuckinghamshire HP12 4EG

ViiV Healthcare UK Ltd

Stockley Park WestUxbridgeMiddlesex UB11 1BT

Sponsors have provided support towards the venue, equipment and catering costs of this meeting,but have had no input into, or influence over, the agenda or content or selection of speakers.

Sponsors will have exhibition stands at this meeting promoting their products.

progress in virology · 0910–0915 introduction chairs: professor anna maria geretti, institute of...

Documents